Perioperative outcomes of cytoreductive surgery for tumours of colorectal or appendiceal origin with ovarian involvement
Details
Publication Year 2023-07,Volume 128,Issue #1,Page 66-74
Journal Title
Journal of Surgical Oncology
Publication Type
Research article
Abstract
BACKGROUND AND OBJECTIVES: Ovarian metastases (OM) are a common site for metastases in gastrointestinal tumours with peritoneal disease. This study aimed to evaluate perioperative complications between patients with and without OM following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal/colorectal cancer. METHODS: Female patients undergoing CRS +/- HIPEC for appendiceal/colorectal tumours at a single centre from 2009 to 2020 were analysed. Patients were grouped according to presence or absence of OM at the time of CRS. RESULTS: The study included 318 patients, 72 (22.6%) had OM. Operation duration was longer for patients with OM (332 vs. 276 min, p < 0.0001). Patients with OM achieved higher rates of complete cytoreduction (93% vs. 79%, p = 0.006) despite a higher peritoneal carcinomatosis index (13 vs. 7, p < 0.001) and were more likely to require a blood transfusion (32% vs. 19%, p = 0.024) and a stoma (24% vs.10%, p = 0.005). Increasing age and presence of abdominal symptoms were independent predictors of major and all-cause morbidity, respectively. The presence of abdominal symptoms was independently associated with all-cause morbidity in the OM group. CONCLUSION: These results may assist with preoperative counselling. Prospective multicentre datasets are needed to evaluate morbidity in one- versus two-stage approaches for those with abdominal symptoms and OM.
Publisher
Wiley
Keywords
Humans; Female; Cytoreduction Surgical Procedures/adverse effects; Prospective Studies; *Peritoneal Neoplasms/surgery/drug therapy; *Colorectal Neoplasms/pathology; *Appendiceal Neoplasms/pathology; *Hyperthermia, Induced/adverse effects; Combined Modality Therapy; Survival Rate; Retrospective Studies; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; perioperative morbidity
Department(s)
Surgical Oncology
PubMed ID
36942464
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-11 06:23:40
Last Modified: 2023-07-11 06:25:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙